Foundation Medicine said Tuesday that it has expanded an ongoing collaboration with Bristol Myers Squibb to include companion diagnostic development for the pharma firm's investigational tyrosine kinase inhibitor repotrectinib.

Righton Gene announced on April 9 that in 2022, the company achieved operating revenue of CNY 424 million, up 45.83% year-on-year; attributable net profit of CNY 40,473,600, down 14.49% year-on-year; basic earnings per share of CNY 0.73.

Ultima Genomics and Genome Insight said on Monday that they are collaborating to develop affordable whole-genome sequencing testing for cancer patients.

The UK National Health Service said last week that it would offer genetic testing for Lynch syndrome to all patients diagnosed with bowel and endometrial cancer.

On April 7, 2023, the "Molecular Diagnostics Joint Laboratory" jointly built by the Key Laboratory of Medical Molecular Virology of Fudan University, Ministry of Education/Health and Health Commission/ Academy of Medical Sciences and Liferiver Bio-Tech.

In a new study looking at the long-term effects of hospitalized patients who have acute kidney injury, Johns Hopkins Medicine researchers found that higher levels of certain biomarkers in urine and blood can predict a patient’s risk of developing chronic kidney disease.

BioMérieux said Friday it is seeking US Food and Drug Administration 510(k) clearance that would allow a US launch of its Vitek Reveal rapid antimicrobial susceptibility testing system to help guide treatment of bacterial sepsis.

In the afternoon of March 30, the first batch of hospitals of the International Hospital Accreditation and Certification Standards (China) accreditation and certification kick-off meeting was held in Qianhai, Shenzhen.

Evident Corporation announced that it has been acquired by private equity firm Bain Capital Private Equity from Olympus Corporation pursuant to the definitive agreement signed on August 29, 2022.

The US Department of Health and Human Services' Biomedical Advanced Research Development Authority (BARDA) this week issued a solicitation for proposals for the research and development of immune assays to evaluate responses to COVID-19 vaccines.

Chinese immunodiagnostics market has maintained an overall growth rate of approximately 20% over the past five years, and is expected to reach a market size of CNY 52.4 billion in 2022.

The Berlin, Germany-based firm developed an assay for Marburg virus on its Minoo portable isothermal molecular diagnostic system.

A study of infants in the neonatal intensive care unit in China investigated whether those conceived with assistance had more genetic diagnoses or de novo mutations.

Recently, WillingMed Technology(Beijing) Co., Ltd. announced the completion of a CNY hundreds of millions Series B financing round.

Sysmex Europe and Cerca Biotech said Monday that they have inked a deal for Sysmex to distribute Cerca's molecular breast cancer assay in 13 European markets.